HEALTHCARE
Oncology Fast Facts
Season 2
About This Season
Season 2 of Fast Facts Oncology is a three-part special that focuses on colorectal cancer. We are joined by experts Dr Arvind Dasari, Dr Reetu Mukherji and Dr Ben George.
All Episodes
Episode 3 - Ben George, MD – Perspectives on Real-World Data in Metastatic Colorectal Cancer
This is the third episode in our series on colorectal cancer which aims to update clinicians on the latest developments in the management of colorectal cancer.
In this episode, Dr. Ben George discusses the importance of real-world data in managing metastatic colorectal cancer care outcomes, and the inescapable truths of daily life that impact patient adherence and resilience. He explains how real-world data can be categorised as providing information on either the efficacy or toxicity of treatment, and how clinicians can use this data to guide management.
Episode 2 - Reetu Mukherji, MD – Unmet Needs in Metastatic Colorectal Cancer
This is the second episode in our series on colorectal cancer which aims to update clinicians on the latest developments in the management of colorectal cancer.
In this episode, Dr. Reetu Mukherji discusses unmet needs in the treatment landscape of colorectal cancer. She explains where the greatest needs are in current management, and what research is being done to fill those gaps. Topics discussed include: adding checkpoint inhibitors to combinations and the use of novel molecules. Studies discussed include SEAMARK, TRIDENTE, BAYONET, MOUNTAINEER-03, STELLAR-303 among others.
Episode 1 - Arvind Dasari, MD MS – Emerging Treatments in Colorectal Cancer
This is the first episode in our series on colorectal cancer which aims to update clinicians on the latest developments in treatment.
In this episode, Dr. Arvind Dasari starts by explaining the current management of colorectal cancer, and then outlines the latest developments in immunotherapy and targeted therapies, touching on specific trials presented at ASCO GI 2023. Trials discussed include Phase III SUNLIGHT, Phase III Fresco-2 and PARADIGM.
About the Speakers
Arvind Dasari, MD MS
Dr. Dasari is a medical oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is co-Chair of the MD Anderson multidisciplinary neuroendocrine tumor board and his clinical focus is on neuroendocrine malignancies. Dr. Dasari’s research interests include clinical, translational and outcomes work in gastrointestinal cancers. He is currently a member of the NCI Task Force for Neuroendocrine Tumors, is co-Chair of the SWOG Neuroendocrine Subcommittee and also chairs the NANETS’ Continuing Education Committee. Dr. Dasari is passionate about the advancement of treatment options for patients with cancer.
Reetu Mukherji, MD
Dr. Mukherji is a gastrointestinal medical oncologist and Assistant Professor of Medicine at MedStar Georgetown University Hospital. She also leads the medical oncology department’s clinical and research focus on upper gastrointestinal malignancies, including esophageal and gastric cancers, at the Georgetown Lombardi Comprehensive Cancer Center. In her clinical work, she primarily cares for patients with gastrointestinal cancers. Dr. Mukherji’s research interests are in patients with gastrointestinal tumors—looking at novel therapeutics and novel biomarkers. Dr. Mukherji strongly believes in the value of working collaboratively with patients, their support systems, and multi-disciplinary teams to deliver the highest level of care and support through their cancer diagnosis.
Ben George, MDr
Dr. George is a gastrointestinal medical oncologist and Associate Professor of Medicine at the Medical College of Wisconsin. His practice has entirely consisted of gastrointestinal malignancies for over a decade. He is also Medical Director of the clinical trials office at the Medical College of Wisconsin, where his research focuses on novel biomarkers and novel treatments for gastrointestinal cancers. Dr. George has been involved with several trials that have advanced the treatment of gastrointestinal cancers, and he is passionate about continuing to push for advancements in cancer care.
